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Abstract
Background: Heparan sulfate proteoglycans (HSPGs) are complex molecules involved in the growth, invasion and
metastatic properties of cancerous cells. This study analyses the alterations in the expression patterns of these
molecules in right sided colorectal cancer (CRC), both metastatic and non-metastatic.
Methods: Twenty right sided CRCs were studied. A transcriptomic approach was used, employing qPCR to
analyze both the expression of the enzymes involved in heparan sulfate (HS) chains biosynthesis, as well as the
proteoglycan core proteins. Since some of these proteoglycans can also carry chondroitin sulfate (CS) chains, we
include the study of the genes involved in the biosynthesis of these glycosaminoglycans. Immunohistochemical
techniques were also used to analyze tissue expression of particular genes showing significant expression
differences, of potential interest.
Results: Changes in proteoglycan core proteins differ depending on their location; those located intracellularly or
in the extracellular matrix show very similar alteration patterns, while those located on the cell surface vary greatly
depending on the nature of the tumor: glypicans 1, 3, 6 and betaglycan are affected in the non-metastatic tumors,
whereas in the metastatic, only glypican-1 and syndecan-1 are modified, the latter showing opposing alterations in
levels of RNA and of protein, suggesting post-transcriptional regulation in these tumors. Furthermore, in non-
metastatic tumors, polymerization of glycosaminoglycan chains is modified, particularly affecting the synthesis of
the tetrasaccharide linker and the initiation and elongation of CS chains, HS chains being less affected. Regarding
the enzymes responsible for the modificaton of the HS chains, alterations were only found in non-metastatic
tumors, affecting N-sulfation and the isoforms HS6ST1, HS3ST3B and HS3ST5. In contrast, synthesis of the CS chains
suggests changes in epimerization and sulfation of the C4 and C2 in both types of tumor.
Conclusions: Right sided CRCs show alterations in the expression of HSPGs, including the expression of the cell
surface core proteins, many glycosiltransferases and some enzymes that modify the HS chains depending on the
metastatic nature of the tumor, resulting more affected in non-metastatic ones. However, matrix proteoglycans and
enzymes involved in CS fine structure synthesis are extensively modified independetly of the presence of lymph
node metastasis.
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Background
Malignances originating in the gastrointestinal tract in-
clude pathologies like esophageal, gastric, pancreatic, he-
patocellular or colorectal cancer which are responsible
for about one third of all cases of cancer in the world
[1]. Cancer of the colon and rectum are often combined
and referred to as colorectal cancer (CRC). CRC is the
third most common cancer in both men and women,
and the third leading cause of cancer-related death in
the world [1]. About 90–95 % of CRCs arise sporadically,
and different intrinsic and extrinsic factors are associ-
ated with increased risk of developing these tumors [2].
The remaining 5 to 10 % are due to inherited conditions,
including familial adenomatous polyposis and hereditary
non-polyposis CRC [2].
Although in general CRCs are usually adenocarcin-
omas, arising from the normal mucosa of the large
bowel and are histologically similar in appearances, this
is in fact a heterogeneous disease when considered with
respect to the anatomic location of the tumor, and there
are anatomic, functional and molecular differences be-
tween tumors of the proximal and distal colorectum, in-
cluding differences in the phenotypic expression of
various biomarkers, as well as the fact that they usually
differ in their response to screening tests, the stage at
which they are diagnosed, their etiology and further-
more, their effect on mortality [2]. Microsatellite in-
stability is more common in right sided cancers, and
these tumors usually have an improved prognosis. In
contrast, left sided tumors often display features, such as
mutation in p53 or overexpression of VEGF, that are as-
sociated with poor prognosis [2, 3].
Few advances have been made in the description of
the molecular changes involved in the invasive stages of
CRC tumors; however, various molecular phenotypes
have been associated with aggressive subtypes in these
pathologies [2]. Notably, several of these markers show a
relationship with the heparan sulfate proteoglycans
(HSPGs). As such, p53 has been described to be involved
in the regulation of genes such as SULF2 or heparanase
[4, 5]; MUC1 and HSPGs cooperate in cell-cell dis-
sociation and the invasiveness of colon carcinoma
cells [6]; many members of the TGF-beta cytokine
superfamily bind to heparan sulfate (HS) chains [7];
the Wnt/β-catenin pathway is regulated by glypican-
3 and—4 [8, 9]; and HSPGs regulate the activity of
VEGF, EGF, and other markers related with CRC
[10, 11]. Moreover, recent analysis of trancriptomic
profiles of CRCs representing different stages of
tumorigenesis have identified important changes in
various molecular pathways during tumor develop-
ment and, interestingly, many of the downregulated
genes encode proteins involved in early-phase signal
transduction [12].
HSPGs comprise a reduced and specific group of pro-
teins which are covalently linked to HS glycosaminogly-
can (GAG) chains. HS is a complex biopolymer, initially
created as a chain of alternating D-glucuronic acid
(GlcA) and N-acetyl-D-glucosamine (GlcNAc). At vari-
ous positions, the molecule is modified by a series of
interdependent enzymatic reactions that include N-
deacetylation of GlcNAc, usually followed by N-sulfation
to produce GlcNSO3, thus creating sulfated S-domains.
Within these regions, GlcA may be epimerized to iduro-
nate (IdoA), and O-sulfate groups added at C6 of GlcN
and C2 of IdoA residues. Minor sulfations at C3 of GlcN
and C2 of GlcA may also occur. These chain modifica-
tions result in clusters of flexible, highly sulfated IdoA-
rich regions, separated by more rigid lowly or non-
sulfated regions [13, 14]. HSPGs are ubiquitously present
in tissues, mainly associated with the cell surface and
the extracellular matrix (ECM) [13, 14], and a variety of
both normal and pathological functions have been as-
cribed to them, including cell adhesion and migration,
organization of the ECM, regulation of proliferation, differ-
entiation and morphogenesis, cytoskeleton organization,
tissue repair, inflammation, vascularization and cancer me-
tastasis; the function ultimately depending on the fine
structure of the chains [13–16]. Specific sets of variably
modified disaccharides, usually within the sulfated do-
mains, define binding sites for a multitude of specific
ligands such as cytokines, chemokines, growth factors,
enzymes and enzyme inhibitors, and ECM proteins
[14, 15]. Cells exercise exquisite control over both
HSPG composition and sequence, though this varies
between cell types, developmental stages, and also as
a result of cell transformation in pathological pro-
cesses. It is therefore of interest to analyze in detail
the complete range of changes in the expression of
HSPGs and HS biosynthetic enzymes occurring in
cancer pathologies as well as the effect of these spe-
cific signatures on promoting invasion and metastasis.
In several cancer cells, genes involved in the biosyn-
thesis of HSPGs are either up—or downregulated [17].
Some alterations in expressions of colon cancer HSPGs
have been described, including alterations which affect
the core proteins, as is the case of some syndecans [18],
the relative amounts and structure of the GAGs [19, 20],
or the expression levels of certain enzymes responsible
for the structure of HS saccharidic chains, including gly-
cosyltransferases as EXTL3 [21] or sulfotransferases as
3-OST-2 [22]. However, to date no studies have analyzed
the entire set of genes involved in the synthesis of these
molecules in this pathology.
In this paper, we investigate the expression patterns of
all genes involved in HSPG biosynthesis in CRCs, and
compare them with healthy tissues from the same pa-
tients. Although previous studies have analyzed this
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pathology in a general way, here we take into consider-
ation that these tumors are, as already mentioned, het-
erogeneous in terms of their anatomic location, and
focus our study on right sided malignances. The tumors
were subdivided into two groups depending on the pres-
ence or absence of metastases in lymph nodes, since this
element is a key predictor of progression. The study in-
cludes genes coding for HSPG core proteins and HS
chain synthesis and modification. Taking into account
that some of these PGs can also carry chains of chon-
droitin sulfate (CS), we extended the study to those
genes involved in the biosynthesis of this GAG. The aim
of the work is to increase our knowledge of the struc-
tural alterations of HSPGs in CRCs, which could in the
future prove useful in developing new chemical biology
approaches to the retardation of tumor progression by
modulating deregulated biosynthetic pathways.
Methods
Materials
The following materials were purchased from the manu-
facturers indicated: RNeasy Kit and RNase-Free DNase
from Qiagen (Hilden, Germany); High-Capacity cDNA
Reverse Transcription Kit and PowerSYBR Green PCR
Master Mix from Applied Biosystems (Foster City, CA);
GenElute PCR clean-up kit and 3–3′ diaminobenzidine
from Sigma-Aldrich (St. Louis, MO); Biotin 3′ End DNA
Labeling Kit from Thermo Scientific (Waltham, MA); In
Situ Hybridization Detection System For Biotinylated
Probes, EnVision™ G|2 Doublestain System and Envision
FLEX target retrieval solution of high pH from Dako
(Glostrup, Denmark);. All other chemicals were obtained
from commercial sources and were of analytical grade.
The following antibodies were used in this study: Goat
Anti-heparanase 1 (L-19), rabbit anti-perlecan (H-300),
Goat anti-C4ST-2 (D-20), Rabbit anti-XylT-I (H-74), all
these polyclonal antibodies, as well as Mouse anti-NDST1
(FF-2) monoclonal antibody being purchased from Santa
Cruz Biotechnology, Inc (Santa Cruz, CA). Rabbit anti-
glypican-1 and Rabbit anti-UST, both polyclonal antibodies,
and Mouse anti-endostatin monoclonal antibody were from
Thermo Scientific (Waltham, MA). Mouse anti-CS (CS-56)
monoclonal antibody was from Sigma-Aldrich (St. Louis,
MO), Rabbit anti-heparanase-2 polyclonal antibody from
GeneTex (Atlanta, GA), mouse monoclonal anti-syndecan-
1 (CD138), mouse monoclonal anti-CD34 and rabbit poly-
clonal anti-CD117 all from DakoCytomation (Carpinteria,
CA). Anti-mouse (sc-2020), anti-rabbit (sc-2004) and anti-
goat (sc-2005) secondary antibodies were also from Santa
Cruz Biotechnology (Santa Cruz, CA).
Tissue samples
All the samples used in this study were obtained from
the Tumor Bank at the Institute of Oncology of Asturias
(Asturias, Spain). All the patients were male, and twenty of
the samples were from CRCs while the remaining twenty
were from the corresponding surrounding healthy tissue
from the same patients and were used as control. Diagnoses
were evaluated using hematoxylin-eosin-stained slides of all
samples according to World Health Organization (WHO)
criteria and the snap frozen tissues were stored at −80 °C
prior to isolation of the RNA. Applying the TNM classifica-
tion, all tumors were at the T3 stage (muscularis propria af-
fected) and they were classified into two groups depending
on the presence (at least N1) or absence (N0) of lymph
node metastases, resulting in 10 samples being included in
the first group and 10 in the second. The study was ap-
proved by the Ethics Committee on Clinical Investigation
of the Hospital Universitario Central de Asturias and writ-
ten informed consents from the patients were obtained.
Total RNA isolation and cDNA synthesis
To obtain the RNA, fragments of tissue of between 20
and 30 mg in weight were used. Samples were homoge-
nized using a polytron PT 2100 (Kinematica Inc; Bohemia,
NY), and RNA was isolated using the RNeasy kit, follow-
ing the manufacturer’s specifications. To ensure removal
of residual contaminating DNA, samples were subjected
to treatment with RNase-free DNase during the purifica-
tion process itself. The concentration of RNA obtained
was determined spectrophotometrically by measuring ab-
sorbance at 260 nm of a 1:50 dilution using a BioPhotom-
eter (Eppendorf; Hamburg, Germany). The samples were
divided into aliquots of 10 μl and used for reverse tran-
scription reactions or stored at −20 °C until further use.
cDNA synthesis was carried out using the High
Capacity cDNA Transcription Kit following the manufac-
turer’s specifications. The reactions were performed using
a thermocycler iCycler IQ (BioRad; Hercules, CA), using
2 μg of RNA as starting material. The reaction products
were cleaned using the PCR Clean-Up GenElute kit in line
with the manufacturer’s instructions. Finally, the aliquots
containing the cDNA were diluted 1:20 with water and
used for qRT-PCR assays or stored at −20 °C until use.
qRT-PCR reactions
In all cases, specific oligonucleotides were designed on
different exons or exon junctions, using the program
Primer 3. (http://biotools.umassmed.edu/bioapps/pri-
mer3_www.cgi). The size of the amplicon in all cases
was between 70 and 150 base pairs, ensuring wher-
ever possible that the Tm was above 77 °C. The the-
oretical Tm for each amplicon was determined using the
program Biomath (http://www.promega.com/a/apps/bio-
math/?calc=tm.). Primer sequences are presented in
Additional file 1.
At least four repetitions of all the qRT-PCR reactions
were carried out in a final volume of 10 μl, according to
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the manufacturer’s specifications, using 1 μl of the
cDNA dilution as template, with 2 μl of primer pair mix
(200 nM final concentration) and 5 μl of SYBR Green
mix, assembled in 96 well microtiter plates. The plates
were sealed with optical film and centrifuged at
2500 rpm for 5 min before being placed in a Real-Time
ABI Prism Detection System device (Applied Biosystems;
Foster City, CA) and the following cycling conditions
imposed: 95 °C for 10 min, 40 cycles of 95 °C for 15 s
followed by 60 °C for 60 s. Following the thermal cycling
and data collection steps, amplimer products were an-
alyzed using a melt curve program (95 °C for 1 min,
55 °C for 1 min, then increasing by 0.5 °C per cycle
for 80 cycles of 10 s each). For each amplification the
presence of a single peak with a Tm corresponding to
that previously calculated was verified. Actin was included
on each plate as a control gene to compare run variation
and to normalize individual gene expression.
Data analysis
To calculate the efficiencies of amplification for each gene
we used the program LinRegPCR (http://www.hartfaalcen-
trum.nl/index.php?main=files&fileName=LinRegPCR.zip&-
sub=LinRegPCR), using the best correlation coefficient
(considering a minimum of 3 points within the window of
linearity) and establishing the average of all positive amplifi-
cations. At least 4 replicates of each reaction were carried
out, with the number of replicates being increased in those
reactions that showed ambiguity or dispersion of results.
The values of differential expression of the genes of interest
were expressed as has been described previously [23]. A
non parametric Wilcoxon test was used for the statistical
analysis of the experiments, using a level of significance of
p < 0.05. All analyses were performed using the program
Statistica for Windows (Statsoft Inc; Tulsa, OK).
Riboprobe preparation
Specific sense and antisense riboprobes for syndecan-1




The length of the probes was adjusted to between 34
and 36 nucleotides, the content of G + C to between
48 % and 62 % and Tm was always above 75 °C. The
probes were labeled with Biotin kit 3 ′End DNA Label-
ing Kit according to the manufacturer’s specifications.
Chromogenic in situ hybridization (CISH)
To perform the hybridizations, paraffin embedded tissue
sections were treated with xylene to render them diaph-
anous, the paraffin later being removed by passing it
through decreasing alcohol concentrations until water
was reached. The samples were then incubated at pH 9
in DAKO K8005 buffer for 30 min at 90 °C to facilitate
the exposure of cellular RNA. Subsequently, the prepara-
tions were washed with sterile tris-buffered saline (TBS),
and incubated with labeled probes at a dilution of 1:2.5
in sterile water in a DAKO hybridization oven for 5 min
at 95 °C, followed by 15.5 h at 62 °C. Then, the prepara-
tions were washed with TBS for 10 min, followed by a
second 5 min wash. The entire procedure was carried
out using the In Situ Hybridization Detection System for
Biotinylated Probes according to the manufacturer’s
specifications. Sections were fixed, mounted and exam-
ined with a Leica DMR microscope (Wetzlar, Germany).
Visualization was carried out using a DFC295 Leica
camera.
Immunohistochemistry
Tissue sections were dewaxed as described in the previ-
ous section. Rehydrated sections were rinsed in phos-
phate buffered saline (PBS) containing 1 % tween-20.
Sections were heated in high pH Envision FLEX target
retrieval solution at 65 °C for 20 min and then incubated
for 20 min at room temperature in the same solution.
Endogenous peroxidase activity (3 % H2O2) and non-
specific binding (33 % fetal calf serum) were blocked and
the sections were incubated overnight at 4 °C with primary
antibodies using a 1:100 dilution. Secondary antibodies
were used at a 1:100 dilution. 3–3′ diaminobenzidine was
used as a chromogen. Finally, samples were counterstained
with hematoxylin, dehydrated and mounted in Entellan®
(Merck, Germany). The sections were studied and photo-
graphed (20X and 40x objective) under a light microscope
(Nikon—Eclipse 80i) (Nikon Corporation, Tokio).
Results
Analysis of differential gene expression
We investigated the differential expression of practically
all the known genes involved in the defined steps of the
biosynthesis of HSPGs in CRCs. We divided the sample
into two groups taking the presence or absence of me-
tastases in lymph nodes as the key indicator. 10 samples
were obtained from patients lacking metastases; their
mean age was 65 ± 16 years; histological grade in all
cases was moderate; the average tumor size was 5.5 ± 1.8
x 3.9 ± 1.8 cm. In addition, 10 samples were obtained
from patients who showed lymph node metastases in
100 % of cases, their mean age was 69 ± 8 years; histo-
logical grade was moderate; the average tumor size was
4,7 ± 0,9 x 4.4 ± 1,7 cm.
We used qRT-PCR to perform a quantitative analysis
of mRNA expression. In many of the genes in which we
were able to detect differences between normal tissues
and tumors, we complemented this test by determining
the expression using histological techniques, including
in situ hybridizations and immunohistochemistry.
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Differential expression of genes encoding core proteins
carrying HS chains
HS occurs in cells and the ECM as PGs [24]. Two gene
families, syndecans and glypicans, account for most cell
surface HSPGs, each of which consists of 4 and 6 iso-
forms, respectively (SDC1-4 and GPC1-6). Within the
syndecans group, no significant differences in the levels
of transcripts of isoforms 2, 3 and 4 could be detected in
any tumor group, regardless of the presence or absence
of lymph node metastasis (Fig. 1a and b). However,
syndecan-1 mRNA appeared overexpressed approxi-
mately 8 fold in metastatic tumors only (p = 0.02, Fig. 1c),
the overexpression occurring in 90 % of the metastatic
CRCs analyzed. Changes in syndecan-1 were also evalu-
ated immunohistochemically using monoclonal anti-
SDC1. Metastatic tumors showed appreciable levels of
immunoreactivity, a similar intensity to that detected in
the normal tissues from the same patients (Fig. 2a and c).
In contrast, and surprisingly, the metastatic tumors
showed a dramatic decrease in staining, which largely dis-
appeared, while labeling was nitidus in the adjacent nor-
mal mucosa (Fig. 2b and d). The divergence between the
results obtained for the quantification of mRNA levels by
qRT-PCR and the immunohistochemical analysis of the
protein suggested the value of using CISH to clarify the
situation. These was done using biotinylated probes for
SDC1, which showed a positive hybridization in normal
and tumoral cells, both metastatic and non-metastatic,
consistent with the differential transcription data obtained
by qRT-PCR (Fig. 2e, f and g).
Analysis of the expression levels of the different glypi-
cans revealed the presence of transcripts for all of the 6
different isoforms, although their levels varied widely de-
pending on the particular species examined. We could
not detect statistically significant differences for isoforms 2,
4 and 5, associated with tumor transformation. GPC1 was
the only isoform that appeared underexpressed in both
metastatic and non-metastatic tumors (Fig. 1a and b); in
metastatic tumors, its levels were reduced in 80 % of
the cases analyzed (p = 0.03), being around 25 % of
those determined in healthy tissues (Fig. 1c); mean-
while, in non metastatic tumors, its levels were reduced
in all cases analyzed (p < 0.01), and their values were
around 18 % of those determined in healthy tissues
(Fig. 1c). Analysis of protein expression by immunohis-
tochemistry revealed the existence of strong staining in
the epithelial cells, although only in isolated cells dis-
playing neuroendocrine differentiation (Fig. 2h). Immu-
nostaining dropped dramatically in the tumor samples,
particularly in non-metastatic tumors (Fig. 2i and J).
Fig. 1 Differential transcription of genes encoding HSPGs. a, b Relative transcript abundance of mRNAs for HSPGs, grouped according to their
topographic location: on the cell surface, in the extracellular matrix or intracellular. Relative abundance for healthy tissues (gray bars) and tumors
(black bars) are plotted on a log scale for each gene assayed and the spreads represent the standard deviations. Genes that display significant
differences in their transcription levels are highlighted. a Non-metastatic CRCs. 2: glypican-1 (p < 0.01); 3: glypican-3 (p = 0.018); 4: glypican-6
(p = 0.02); 5: betaglycan (p < 0.01); 6: perlecan (p = 0.01); 7: collagen XVIII (p < 0.01); 8: serglycin (p = 0.01). b Metastatic CRCs. 1: syndecan-1
(p = 0.02); 2: glypican-1 (p = 0.03); 6: perlecan (p = 0.015); 7: collagen XVIII (p = 0.04); 8: serglycin (p = 0.017). c Relative expression ratio of genes that
show statistically significant differences in expression in non-metastatic (●) or metastatic (■) CRCs. Values on the Y axis are represented on a
logarithmic scale
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In addition to GPC1, decreases in the levels of transcrip-
tion of glypicans 3 and 6 were also detected, although only
in non-metastatic tumors (Fig. 1). GPC3 appeared under-
expressed in 100 % of non-metastatic CRCs analyzed
(p = 0.018), with the average decrease being approximately
14 fold (Fig. 1c), while only 50 % of metastatic tumors
showed alteration in levels of this glypican. Meanwhile,
GPC6 mRNA levels were reduced almost 4 fold in 80 % of
non-metastatic tumors (p = 0.02), a percentage that halved
in the case of tumors with lymph node metastases (Fig. 1c).
Fig. 2 Immunolocalization of cell HSPGs. a-g Histological localization of syndecan-1 expression. a-d Localization of syndecan-1 in transition area
between normal colon mucosa and tumor using immunohistochemistry. a, c Non-metastatic tumor; arrows indicate the retention of staining in
the tumor region; b, d Metastatic tumor; arrows indicate the loss of staining in the tumor region, magnification A and B 20X, magnification C and
D 100X; e-g CISH for syndecan-1 in CRCs. e Normal tissue; f Non-metastatic tumor; g Metastatic tumor; magnification 400X. h-j. Immunolocalization
of glypican-1 expression. h, Normal mucosa. Intense staining appears in cells with neuroendocrine differentiation (arrows), whereas other epithelial
cells show weak to moderate staining. i Non-metastatic CRC showing extremely weak staining. J Metastatic tumor showing weak staining
levels; magnification 400X. k-l Immunolocalization of mast cells using CD117 antibody. Localization of mast cells in transition area between
normal colon mucosa and tumor. k Non-metastatic CRC; l Metastatic CRC; magnification 200X. Arrows indicate the staining of mast cells in
the normal mucosa. The asterisks show the tumor area, in which there is no detectable labeling
Fernández-Vega et al. BMC Cancer  (2015) 15:742 Page 6 of 20
Beside syndecans and glypicans, the other HSPGs present
in the cell membrane include betaglycan (TGFBR3) and
CD44v3 isoform [24]. qRT-PCR analysis showed the pres-
ence of transcripts of these genes in normal tissues and in
tumors, both metastatic and non-metastatic (Fig. 1a and b).
We were unable to determine significant differences in
their transcript levels, except for betaglycan in non-
metastatic tumors, where it appeared underexpressed in
90 % of cases (p < 0.01), with values around 8 times lower
than those of normal tissues (Fig. 1c).
Serglycin is a cell-associated PG that differs from cell
surface HSPGs in that it is located intracellularly [25].
qRT-PCR analysis of serglycin transcripts in non-
metastatic CRCs showed a decrease in 100 % of the tu-
mors investigated (p = 0.01), the average reduction being
around 10 fold (Fig. 1). When the study was performed on
metastatic CRCs, a decrease in RNA levels affecting 70 %
of the tumors was also detected (p = 0.017), though the
average reduction was half of that observed in the non-
metastatics (Fig. 1). The principal intracellular locations of
serglycin are mast cell secretory granules [25], prompting
us to apply immunohistochemical studies to detect these
cells using the antibody CD117. The analysis showed a
drastic reduction of the population of mast cells in tumors
compared to non-tumor colon mucosa (Fig. 2k and l).
When evaluating the extracellular matrix PGs, no sig-
nificant differences were detected for agrin. However,
perlecan and collagen XVIII showed significant down
regulations in tumoral samples. The transcription levels
of perlecan decreased in 90 % of both non-metastatic
and metastatic tumors (p = 0.01 and 0.015), respectively
reaching values around 20 and 30 fold lower than those
of healthy tissues. These results were also observed
using immunohistochemistry, where perlecan displayed
only a faint staining of the cytoplasm and basement
membranes of normal tissues, while weaker staining was
observed in the tumor stroma of metastatic and non-
metastatic CRCs (Fig. 3a, b and c). Moreover, a significant
Fig. 3 Immunolocalization of ECM HSPGs. Immunolocalization of perlecan expression. a Normal mucosa showing positive staining in the cell
cytoplasm and in the basement membranes, magnification 400X. b, c Non-metastatic (b) and metastatic (c) tumors showing weak and
focal staining in the cells and the tumor stroma; magnification 400X. d-g Immunolocalization of collagen XVIII expression. d Normal mucosa. Staining
appears at arteriolar vessels in the lamina propria (arrows). f, g Non-metastatic (f) and metastatic (g) CRCs showing no positive immunoreactivity.
e Tumor neovascularization displayed by positive immunoreactivity for CD34 antibody. Magnification 200X
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subexpression of collagen XVIII was also detected, around
6 and 4 times lower than in normal tissue for metastatic
and non-metastatic tumors respectively (p < 0.01 and
p = 0.04) and was observed in all cases of non-
metastatic CRCs analyzed and in 70 % of metastatic.
Immunohistochemical analysis revealed that healthy
tissues expressed the protein mainly at arteriolar ves-
sels in the lamina propria (Fig. 3d); in contrast, the
expression of the protein was not observed in the tu-
mors, although capillary neovascularization was able
to be detected, evidenced by immunostaining using
the anti-CD34 antibody (Fig. 3e, f and g).
Differential expression of genes encoding
glycosyltransferases involved in common linkage region
sequence and GAG chain synthesis
HS and CS/dermatan sulfate (DS) chains are synthesized
through the cooperation of multiple biosynthetic en-
zymes in the Golgi. The first step requires an array of
glycosyltransferases (GTs) which generate a tetrasac-
charide gycan linker on a cognate serine residue of the
PG core. This linker is shared by HS and CS/DS chains
and its sequence is integrated by xylose-galactose-
galactose-GlcA [25, 26]. HS chain extension requires
the subsequent transfer of a GlcNAc residue, followed
by the sequential addition of alternative GlcA and
GlcNAc residues to generate a non-branched polymer.
In contrast, the addition of an N-acetyl-D-galactosamine
(GalNAc) rather than GlcNAc directs the pathway to-
wards the biosynthesis of CS/DS. In this case, chain exten-
sion takes place through the sequential addition of
alternative GlcA and GalNAc residues [26, 27].
We analyzed the differential transcription of the vari-
ous genes known to be involved in the biosynthesis of
the tetrasaccharide linker: XYLT1 and XYLT2, which are
responsible for the initial transfer of the xylose residue;
FAM20B, which encodes a xylose kinase that catalyzes
the transient phosphorylation of this residue; B4GALT7,
and B3GALT6, responsible for sequential addition of the
two residues of galactose; and B3GAT1, B3GAT2 and
B3GAT3, which encode enzymes responsible for the
transfer of GlcA [28]. Four of these transcripts appeared
downregulated in non-metastatic CRCs, while only one
was in metastatic tumors (Fig. 4). Transcript levels of
the three genes involved in the transfer and modification
of the xylose residue, XYLT1, XYLT2 and FAM20B ap-
peared altered in non-metastatic patients; expression of
both XYLT1 and FAM20B decreased by over 80 % in
90 % of patients, while XYLT2 expression fell by around
60 % in 80 % of analyzed cases (p = 0.008, p = 0.02
and p = 0.017 respectively). Conversely, in metastatic
tumors no statistically significant differences in the
Fig. 4 Differential transcription of genes encoding the glycosyltransferases involved in the biosynthesis of HS and CS chains. a, b Relative
transcript abundance of mRNAs for enzymes involved in the synthesis of the tetrasaccharide gycan linker, the initiation and elongation of HS
chains, and the initiation and elongation of CS chains. Relative abundance for healthy tissues (gray bars) and tumors (black bars) are plotted on a
log scale for each gene assayed and the spreads represent standard deviations. Genes that display significant differences in their transcription
levels are highlighted. a Non-metastatic CRCs. 1: xylosyltransferase I (p < 0.01); 2: xylosyltransferase II (p = 0.017); 3: xylosylkinase (p = 0.017); 4:
beta-1,3-glucuronyltransferase 1 (p = 0.018); 5: exostosin glycosyltransferase 1 (p = 0.01); 6: chondroitin sulfate N-acetylgalactosaminyltransferase 1
(p = 0.018); 7: chondroitin sulfate N-acetylgalactosaminyltransferase 2 (p = 0.011); 8: chondroitin sulfate synthase 1 (p = 0.01); 9: chondroitin sulfate
synthase 3 (p = 0.01). b Metastatic CRCs. 4: beta-1,3-glucuronyltransferase 1 (p = 0.018); 10: chondroitin polymerizing factor (p = 0.043). c Relative
expression ratio of genes that showed statistically significant differences in expression in non-metastatic (●) or metastatic (■) CRCs. Values on the Y axis
are represented on a logarithmic scale
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expression levels of any of these genes were detected
(Fig. 4). We carried out an analysis of XYLT1 protein
expression using immunohistochemistry which
showed the existence of staining in the normal tissues
that could not be detected in experiments performed
using non-metastatic tumor samples (Fig. 5a and b).
No differences in expression were observed for
B4GALT7, and B3GALT6, or for two of the three iso-
forms involved in the transfer of the first GlcA resi-
due, B3GAT2 and B3GAT3, although B3GAT2 did
display very low expression values which varied de-
pending on the patients analyzed (Fig. 4a and b).
Conversely, B3GAT1 showed a statistically significant
subexpression, both in non-metastatic tumors, where
its levels were reduced by around 20 fold, and in
metastatics, where the decrease was roughly about 6
fold, affecting in both cases at 90 % of patients tested
(p = 0.018 and p = 0.04 respectively).
In no case did the mRNA levels of the GTs involved in
the synthesis of the HS chains appear modified in CRCs,
neither those enzymes involved in the transfer of the
first GlcNAc residue or those in charge of the subse-
quent polymerization. The only exception being EXT1,
which appeared downregulated on average about 4 fold
(p = 0.01) in 90 % of patients with non-metastatic tu-
mors (Fig. 4).
By contrast, the biosynthesis of CS/DS chains appears
to be seriously affected in non-metastatic tumors, as in-
dicated by the subexpression of 4 of the 5 genes involved
(Fig. 4a). The two GTs involved in the transfer of the
Fig. 5 Immunolocalization of genes involved in the biosynthesis of HS and CS chains. a, b Immunolocalization of XYLT1 expression. a Normal
mucosa showing weak to moderate staining. b Non-metastatic CRC, in which there is no detectable labeling; magnification 400X.
c-e Immunolocalization of NDST1 expression. c Normal mucosa showing weak to moderate staining in the cell cytoplasm. d, Non-metastatic CRCs
showing a decrease in the intesity of the staining. e Metastatic CRCs showing a similar staining intensity to that of healthy tissue. Magnification 400X
f Localization of CHST12 expression in transition area between normal colon mucosa and tumor. Arrows indicate the staining of cells in the
normal mucosa. The asterisks show the tumor area, in which the intensity of the labeling diminishes. Magnification 400X. g, h Immunostaining
of UST. g Normal mucosa showing cytoplasmic staining in epithelial cells. h Non-metastatic CRC showing a notable decreasing in labeling.
Magnification 400X
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first GalNAc residue, CSGALNACT1 and CSGAL-
NACT2, appeared downregulated an average around
5- and 4 fold in 100 % and 75 % of tumors respect-
ively (p = 0.18 and p =0.011); in addition, the chon-
droitin synthases CHSY1 and CHSY3 reduced their
mRNA levels about 70 % and over 95 % in 90 % and
70 % of the CRCs analyzed respectively (p = 0.01 and
p =0.05). Interestingly, none of the changes in these
transcripts in metastatic tumors were significant, ex-
cept for CHPF (p = 0.04), the only gene not altered in
non-metastatic tumors which appeared overexpressed
around 3 fold (Fig. 4).
Differential expression of genes involved in the
modification of HS chains
The result of the action of all GTs involved in the syn-
thesis of HS is an unmodified chain that consists simply
of repeating GlcNAc-GlcA units. As the chain polymer-
izes, it undergoes a series of modifications; the initial
modification reactions involve removal of acetyl groups
from GlcNAc residues, followed by sulfation of the
amino group which is catalyzed by four different iso-
forms of N-deacetylase/N-sulfotransferases: NDST1-4
[13, 14]. Transcripts of only two of these isoforms,
NDST1 and 2, could be quantified in all healthy and tu-
moral tissues, with NDST3 and 4 being undetectable in
most patients (Fig. 6a and b). Both NDST1 and 2
appeared downregulated in non-metastatic CRCs alone;
NDST1 showed reduced expression in about 75 % on
average (p = 0.008), while the reduction in NDST2 expre-
sion was around 6 fold (p = 0.008), the downregulation
being observed in both cases in 100 % of tumors ana-
lyzed (Fig. 6c). NDST1 expression was also analyzed
at the protein level by immunohistochemistry, with
similar results to those described for the transcript
levels; in normal and metastatic tissues a similar in-
tensity of cytoplasmic staining was observed, while
that of non-metastatic CRCs was reduced in comparison
(Fig. 5c, d and e).
Further modifications of the HS chain include the epi-
merization of GlcA into IdoA which is catalyzed by the
action of the enzyme C5-GlcA epimerase (GLCE), the
addition of sulfate groups at C2 of uronic acid which is
catalyzed by the enzyme HS 2-O-sulfotransferase
(HS2ST1), and the sulfation at C6 of glucosamine resi-
dues, catalyzed by HS 6-O-sulfotransferase isoforms 1–3
(HS6ST1-3) [13, 14]. Neither GLCE nor HS2ST1 showed
any significant alterations at the transcriptional level.
With regard to C6 sulfation, no HS6ST2 transcripts
could be detected, and the levels of HS3ST3 were very
low and displayed considerable variation between pa-
tients; however, HS6ST1 was the major isoform present
in all cases, and furthermore displayed a statistically sig-
nificant decrease in non-metastatic tumors (p = 0.007),
Fig. 6 Differential transcription of genes involved in the modification of HS chains. a, b Relative transcript abundance of mRNAs for enzymes
involved in the modification of HS chains. Relative abundance for healthy tissues (gray bars) and tumors (black bars) are plotted on a log scale for
each gene assayed and the spreads represent standard deviations. Genes that display significant differences in their transcription levels are highlighted.
a Non-metastatic CRCs. 1: N-deacetylase/N-sulfotransferase 1 (p < 0.008); 2: N-deacetylase/N-sulfotransferase 2 (p = 0.008); 3: 6-O-sulfotransferase 1
(p = 0.007); 4: 3-O-sulfotransferase 3B (p = 0.04); 5: 3-O-sulfotransferase 5 (p = 0.009) b Metastatic CRCs. c Relative expression ratio of genes
that show statistically significant differences in expression in non-metastatic (●) or metastatic (■) CRCs. Values on the Y axis are represented
on a logarithmic scale
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values being on average 5 times lower in 100 % of the
cases analyzed (Fig. 6).
The final step in the modification of HS chains during
their biosynthesis in the Golgi involves the addition of
sulfate group at C3 of glucosamine. This reaction is cata-
lyzed by HS 3-O-sulfotransferase isoforms 1–6 (HS3ST1,
HS3ST2, HS3ST3A1, HS3ST3B1, HS3ST4, HS3ST5 and
HS3ST6) [13, 14]. The transcript levels of these enzymes
varied considerably between the different isoforms and
also, for some particular isoforms, between the specific
cases analyzed. However, it was possible to detect signifi-
cant differences, confined to non-metastatic tumors, for
at least two of these molecules, HS3ST3B1 and HS3ST5
(Fig. 6a and b). HS3ST3B1 decreased around 5 fold in all
analyzed CRCs (p = 0.004), and HS3ST5 diminished its
transcription levels over 90 % in 80 % of cases (Fig. 6c).
The final modification of the HS patterning is carried
out at the cell surface by two cell surface sulfatases,
SULF1 and SULF2, which remove glucosamine-6S
groups from specific regions [13, 14]. The transcript
levels of neither of these genes demonstrated alterations
for either type of CRC (Fig. 6).
Differential expression of genes involved in the
modification of CS chains
CS/DS chains are modified to a lesser extent than those
of HS. Two reactions may involve the GalNAc residue:
sulfation at the C4, catalyzed by four different enzymes
(CHST11, CHST12, CHST13 and CHST14), and sulfation
at C6, catalyzed by three distinct enzymes (CHST15,
CHST3 and CHST7). Another two different reactions may
involve the uronic acid residue, including C5 epimeriza-
tion, catalyzed by dermatan sulfate epimerase (DSE), and
the addition of sulfate groups at C2, catalyzed by chondro-
itin uronosyl sulfotransferase (UST) [28].
Sulfation of GalNAc at C4 seems to be strongly af-
fected in CRCs, since transcription levels of 3 of the 4
enzymes involved appeared downregulated, irrespective
of the presence or absence of lymph node metastasis
(Fig. 7a and b). In addition, transcript levels of the only
gene for which no significant differences could be de-
tected, CHST13, were between one and two orders of
magnitude lower than the rest. CHST11 mRNA was the
most abundant species in healthy tissues, and its levels
were reduced an average of approximately 12 fold in
Fig. 7 Differential transcription of genes involved in the modification of CS/DS chains. a, b Relative transcript abundance of mRNAs for enzymes
involved in the modification of CS/DS chains. Relative abundance for healthy tissues (gray bars) and tumors (black bars) are plotted on a
log scale for each gene assayed and the spreads represent standard deviations. Genes that display significant differences in their transcription levels
are highlighted. a Non-metastatic CRCs. 1: chondroitin 4 sulfotransferase 11 (p = 0.008); 2: chondroitin 4 sulfotransferase 12 (p = 0.011); 3:
N-acetylgalactosamine 4 sulfotransferase 14 (p = 0.012); 4: dermatan sulfate epimerase (p = 0.017); 5: uronyl-2-sulfotransferase (p = 0.012).
b Metastatic CRCs. 1: chondroitin 4 sulfotransferase 11 (p = 0.02); 2: chondroitin 4 sulfotransferase 12 (p = 0.025); 3: N-acetylgalactosamine 4
sulfotransferase 14 (p = 0.035); 4: dermatan sulfate epimerase (p = 0.046); 5: uronyl-2-sulfotransferase (p = 0.05). c Relative expression ratio of
genes that show statistically significant differences in expression in non-metastatic (●) or metastatic (■) CRCs. Values on the Y axis are
represented on a logarithmic scale
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metastatic and 9 fold in non-metastatic tumors (p = 0.008
and p = 0.021) (Fig. 7c), affecting in both cases 90 % of the
patients analyzed. Moreover, CHST12 showed a 9 fold
mean downregulation in the non-metastatic CRCs, in
90 % of cases, whereas in metastatic tumors its decrease
was lower, at around 4 fold, and involved only 70 % of
cases (p = 0.011 and p = 0.025). CHST12 protein expres-
sion was also analyzed by immunohistochemistry, and the
results showed that the staining in the normal colonic mu-
cosa was reduced in tumor tissue (Fig. 5f). Finally,
CHST14 showed, on average, a 3 fold deregulation in
80 % of cases for both metastatic and non-metastatic tu-
mors (p = 0.012 and p = 0.035). However, between the
three enzymes involved in C6 sulfation, no significant dif-
ferences could be detected, albeit that CHST7 mRNA
levels were very low and those of CHST15 undetectable
(Fig. 7a and b).
Furthermore, the differential transcription levels of the
two enzymes involved in the modification reactions of
uronic acid residues were significantly altered. DSE de-
creased around 7 fold, affecting 90 % of non-metastatic
and 80 % of metastatic CRCs (p = 0.017 and p = 0.046)
(Fig. 7). Meanwhile, UST decreased 25 fold in non-
metastatic tumors, affecting all patients tested, although
the average decrease in the metastatic tumors was only
4 fold, and in this case only affected 70 % of cases
(Fig. 7). The protein expression of UST was also ana-
lyzed by immunohistochemistry, staining appearing in
the cytoplasm of cells of the normal colonic mucosa,
and was greatly decreased in intensity in tumor tissues,
consistent with the results at the transcription level
(Fig. 5g and h).
Given the extent of the observed alterations in the
expression of genes involved in the synthesis and
modification of CS/DS chains, we also conducted an
analysis of the structure of the saccharide chains by
immunohistochemistry using the specific antibody
CS-56. The results showed a decrease in the intensity
of staining in tumor cells, both non-metastatic and
metastatic (Fig. 8). However, it was also observed that
there was a considerable increase in staining in the
stroma of both types of CRC, appearing with greater
intensity in the non-metastatics (Fig. 8).
Differential expression of genes involved in the
modification of heparanases
Heparanase (HPSE) is an endo-β-D-glucuronidase that
degrades HS, generating biologically active fragments.
Analysis of its transcript levels in non-metastatic CRCs
established the existence of a statistically significant
downregulation (p = 0.013). This decrease was observed
in 70 % of the patients analyzed, the mean reduction be-
ing about 80 % less than in corresponding normal tis-
sues. Interestingly, the dispersion of the results in
healthy tissue was much greater than in tumoral tissues,
the former exhibiting a standard deviation more than
double that of the tumor samples (2.4 versus 1.1 respect-
ively, expressed in cycles of PCR). Furthermore, meta-
static tumors showed greater variability in their levels of
transcription, HPSE mRNA values appearing reduced in
40 % of patients, at the same time as 20 % of patients
showing overexpression, results which combined to pro-
duce the lack of a statistically significant trend (p = 0.13).
HPSE expression was also analyzed by immunohisto-
chemistry, where cytoplasmic immunoreactivity was
Fig. 8 Immunolocalization of CS. a Normal mucosa showing stromal
and cell labeling. b Non-metastatic CRC showing very weak cell
labeling and strong stromal staining. c Metastatic CRC displaying
weak labeling in tumour cells and stroma. Magnification 400X
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observed in normal tissue cells, the intensity of which
decreased in some non-metastatic tumors (Fig. 9a and b).
Heparanase 2 (HPSE2) is a homologue of HPSE which
lacks HS-degrading activity, although it is able to inter-
act with HS with high affinity [29]. Transcripts for this
gene could be detected in 70 % of both healthy and
tumoral tissue of patients with non-metastatic CRCs. Al-
though the difference between tissue types was not sta-
tistically significant (p = 0.34), as with HPSE, there was
much higher dispersion in normal tissue than in tumoral
(4.3 versus 1.5 respectively, expressed in cycles of PCR).
In metastatic CRCs, these gene transcripts were also de-
tected in 70 % of patients, albeit that values were again
highly dispersed. However, the expression could only be
detected in 40 % of the tumor samples of this group,
with positive expression values being similar to those ob-
tained for non-metastatic tumors. Immunohistochemical
analysis of the expression of this protein showed positive
immunoreactivity which was of similar intensity in the
cells of normal mucosa and in the CRCs of those pa-
tients expressing the protein (Fig. 9c and d).
Discussion
CRC is a heterogeneous disease, especially with respect
to features such as genetic and dietary interactions and
the anatomic location of the tumor [2]. Taking into ac-
count the distribution of neoplasia in the colorectum,
CRCs are divided into right sided and left sided bowel
cancer, and the two types show differences in their clin-
ical presentation and surgical management, as well as
functional and molecular differences including the
phenotypic expression of various biomarkers [2, 3]. The
pathogenesis of CRC usually follows a stepwise progres-
sion from benign adenoma to malignant adenocarcin-
oma and distant metastasis, its sequential nature lending
itself to the notion of identifying diagnostic markers.
The expression of HSPGs is markedly altered during
malignant transformation and tumor progression, affect-
ing both the PG core proteins and the GAG chains [30].
Substantial evidence in support of this has been reported
in relation to various tumors, including brain, breast,
lung, skin, pancreas, colon, ovarian and head and neck
[30], and as such abnormal HSPG expression in cancer
and stromal cells can serve as a biomarker for tumor
progression and patient survival [31]. As a result of these
modifications, some processes appear to be affected,
such as cancer cell signaling, growth and survival, cell
adhesion, and differentiation, migration and angiogenesis
[31]. The HS fine structure is determined by cell-type
specific expression of only certain isoforms of some of
the biosynthetic enzymes, notwithstanding the existence
in some specific cases of regulation at the level of trans-
lation or enzymatic catalysis [32–34]. We have therefore
investigated the expression patterns of the genes in-
volved in HSPG biosynthesis in CRCs and compared
their expression patterns to that of healthy tissue from
the same patients. We have centered the study on right
sided tumors due to the fact that there are differences
between them and left sided CRCs. In addition, we have
considered the comparative analysis of two groups of
Fig. 9 Immunolocalization of heparanases. a, b Immunostaining of heparanase. a Normal mucosa showing intense cell labeling; b Non-metastatic
CRC from the same patient showing a decrease in immunostaining. c, d Immunostaining of heparanase 2. Normal mucosa (c) and tumor (d)
samples from the same patient displaying similar immunoreactivity. Magnification 400X
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tumors, both at the T3 stage where the muscularis pro-
pria is affected. Also, we included in these analyses, the
absence of lymph node metastases.
In human cells, two gene families, syndecans and gly-
picans, account for most cell surface HSPGs, although a
few more part-time proteins may appear [24]. Previous
immunohistochemical studies performed with syndecans
in colon cancer have demonstrated a loss of expression
of syndecan-1 in CRCs, some of which have been
found to correlate with tumor stage and metastasis
[35–38]. However, a study analyzing mRNA transcripts of
syndecan-1 did not find significant differences between
normal and cancerous tissues [39], while another, using
colon carcinoma cells, evidenced a decrease in syndecan-1
mRNA levels in most of samples, along with a 2–5 fold in-
crease in syndecan-2, and a decrease in syndecan-4
mRNA which was restricted to highly metastatic cell lines
[18]. In contrast, in the current work, no significant differ-
ences in levels of transcripts of any of the four isoforms
were found in non-metastatic CRCs, while syndecan-1
mRNA alone appeared overexpressed in metastatic tu-
mors. Analyzing the expression of syndecan-1 protein
using immunohistochemistry, provided the noteworthy
finding that non-metastatic CRCs displayed similar immu-
noreactivity to that detected in normal tissues from the
same patients, while the metastatic tumors showed a dra-
matic decrease in staining. Nevertheless, examining tran-
scription at the tissue level by means of CISH showed
positive hybridization in normal as well as tumoral cells,
both metastatic and non-metastatic, consistent with the
qRT-PCR. These data suggests that in the expression of
syndecan-1 in CRCs, additional post-transcriptional
mechanisms, such as protein translation, degradation, in-
hibition by feedback loops or miRNA regulation may be
involved. Post-transcriptional regulation of syndecan-1 ex-
pression has been indicated previously, for example in
pancreatic cancer and peritoneal macrophages [34, 39,
41]. Upregulation of syndecan-1 has also been described
in tumors other than those of the colon, and it has been
postulated that this aberrant expression may play a key
role in promoting growth factor signaling in cancer cells
[30 ]. In contrast, other malignances showed downregula-
tion of this molecule, indicating that this HSPG could well
serve as a prognostic marker in a cancer-type-specific
manner [30 ]. Furthermore, at the transcriptional level,
syndecan-1 modulation has been related with the expres-
sion of other PGs, as well as with genes involved in bio-
synthesis and sulfation of HS chains [40].
The glypicans constitute a six-member family of cell
surface HSPGs that are glycosylphosphatidylinositol-
linked to the cell membrane. Their expression is cell-
type and developmental-stage specific and they are im-
plicated in the regulation of several signaling pathways,
including Wnts, Hedgehogs, FGF, bone morphogenic
protein and insulin-like growth factor, where they can ei-
ther stimulate or inhibit activity depending on the bio-
logical context [41]. Because of their biological roles,
they influence tumor progression and their abnormal ex-
pression has been described in various human tumors
[31]. In this work, analysis of the transcription of the 6
genes in CRCs showed deregulations for isoforms 1, 3
and 6 in non-metastatic tumors, while only glypican-1
transcription was significantly altered in metastatic, and
to lesser extent than in non-metastatic.
Glypican-1 is, with −3 and −5, the isoform most widely
associated with the tumorigenic process. Immunohisto-
chemical analysis of glypican-1 protein showed a very
weak staining in most of the cells, although certain spe-
cific ones displaying neuroendocrine features showed in-
tense immunostaining, On the other hand, it must be
taken into account that the values of transcription quan-
tified by PCR are not probably revealing these differ-
ences, since it must be considered that the data are
affected by the decrease or absence of neuroendocrine
cells with high expression levels in the tumor stroma.
The disappearance of the expression of this protein has
previously been described in tumor epithelial cells in
prostate cancer, although with high expression being
maintained in tumor stroma [42 ]. Conversely, glipican-1
overexpression has been described in certain tumors,
although with some peculiarities depending on the
neoplasia: in gliomas, where it acts to enhance FGF
signaling and mitogenesis [43]; in pancreatic cancer,
both in the cancer cells and the adjacent fibroblasts
[44]; in high-grade breast cancer tumors [45]. Inter-
estingly, in neuroendocrine neoplasias derived from
the large bowel, GPC1 expression has been shown to
be intense in well-differentiated tumors, but far less
in poorly differentiated, a feature that seems to be
shared with other neuroendocrine tumors, independ-
ently of their topography [46].
Glypican-3 is though to be the species for which most
expression alterations in tumors have been described. In
this work, this isoform appeared downregulated in all
the non-metastatic CRCs analyzed, while only 50 % of
metastatic tumors showed alteration in its level. Down-
regulation of glypican-3 has been described in many
tumor types, including breast, lung, gastric, and ovarian
cancers and mesothelioma [41]. However, in tumors ori-
ginating from tissues where glypican-3 expression is re-
stricted to the embryo, its expression tends to reappear
with malignant transformations [41]. The effects of the
loss of this protein on tumor development are compat-
ible with its function as a tumor supressor, as this mol-
ecule can inhibit cell proliferation and also induces
apoptosis [47]. However, GPC3 overexpression can act
as an oncogene in some tumors, such as hepatocellular
carcinomas [48].
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Besides isoforms −1 and −3, 80 % of non-metastatic
tumors tested here also displayed a decrease in the tran-
script levels of glypican-6, a percentage that was halved
in CRCs with lymph node metastases. Unlike the other
isoforms, relatively little is known concerning the ex-
pression or functional roles of glypican-6 in tumors.
Reduced expression or loss of function of this isoform
has been described in retinoblastoma and autosomal-
recessive omodysplasia [49, 50]; however, breast car-
cinoma invasion has been reported to be promoted
through induction of glypican-6 by the transcriptional
factor NFAT (nuclear factor of activated T-cells) using
non-canonical Wnt5a signaling [51].
In addition to glypicans and syndecans, in this study
we also analyzed the expression levels of betaglycan and
CD44v3. These molecules are part time membrane
HSPGs, that is, they exist either with or without HS
chains [24]. CD44 comprises a family of heterogeneous
integral membrane PGs derived from a single gene. The
HS attachment site is located on exon 8 (CD44v3) [52],
and thus we designed primers to specifically detect this
isoform. CD44v3 did not show statistically significant
differences in any type of CRCs; this data differs from
previous studies where the expression of this protein in
colon tumors was found to be related to more advanced
pathological stage and poorer prognosis [53]; however,
further detailed observation of our analysis showed that
for 60 % of patients with metastatic tumors, this protein
was indeed overexpressed, the scattering of the data hav-
ing lead to the negative results in the initial statistical ana-
lysis. This phenomena was not observed in tumors lacking
lymph node metastases, thereby supporting the results ob-
tained in previous studies, which suggests a role for
CD44v3 in invasion and metastasis by CRC cells [53].
The other part time HSPG analyzed, betaglycan, ap-
peared underexpressed around 8 fold in non-metastatic
CRCs, and about half of the patients with metastatic tu-
mors exhibited under-expression of the protein, a differ-
ence that was not statistically significant in this case.
Betaglycan is a ubiquitously expressed membrane-bound
TGF-β superfamily coreceptor, also known as type III
TGF-β receptor, which acts to regulate the cellular ac-
tions of TGF-β and inhibin [54]. The expression of beta-
glycan in tumor cells appears to play an important role
in the progression of cancer, and reduced expression of
this PG has been associated with advanced stage in dif-
ferent types of cancers [55]. In several neoplastic cells
the loss of betaglycan facilitates the epithelial–mesen-
chymal transition, and a suppressor role for betaglycan
in epithelial carcinogenesis has been proposed [55].
However, a correlation between high levels of this PG
and invasiveness has been described in breast cancer cell
lines [56], and increased expression has been seen in
high-grade non-Hodgkin’s lymphomas and B-cell chonic
lymphocytic leukemia [57, 58], suggesting a promoting
role in these cases.
Two of the three extracellular matrix HSPGs examined
here showed significant downregulation in tumoral sam-
ples: perlecan and collagen XVIII. Perlecan expression
was downregulated at both the mRNA and protein level
in tumors, independent of the presence or absence of
lymph node metatases. Perlecan is a critical regulator of
growth factor-mediated signaling and angiogenesis, and
is fundamental for the maintenance of basement mem-
brane homeostasis [59], suggesting that its alteration could
play an important role in CRC progression. Although ex-
pression of perlecan is enhanced in a number of tumor
types, in some other cases, such as lung carcinoma and
hepatocellular carcinoma cells, its levels are undetectable
and in these cases, it has been suggested that the lack of
perlecan may favor the diffusion of growth factors, leading
to tumor growth and metastasis [60].
Collagen XVIII transcription levels were also downreg-
ulated in CRCs, both metastatic and non-metastatic. Im-
munohistochemical analysis of the protein revealed that
its expression was mainly at arteriolar vessels in the lam-
ina propria in healthy tissues, while in both tumor types
its expression could not be detected, although they dis-
played positive immunostaining using anti-CD34 anti-
body. CD34 is a cell surface glycoprotein widely used as a
marker of vascular endothelial cells [61]. Collagen XVIII
expression is widespread throughout vascular basement
membranes, and can negatively modulate angiogenic pro-
cesses by mediating interactions between endothelial cells
and underlying extracellular matrix components [62]. The
expression of this HSPG has been studied in various ma-
lignances and found to vary between different cancer
types; increasing in ovarian or pancreatic cancer, while
diminishing in liver and oral cancer [31].
Serglycin is the only characterized PG which is located
intracellularly, although it has also been documented as
a secretory product that may appear incorporated into
the ECM or associated with the surface of target cells
[25]. In this work, transcript levels of this gene were sig-
nificantly reduced, both in metastatic and non-metastatic
tumors, albeit more intense in the latter. Serglycin is
mainly found in hematopoietic and endothelial cells,
although some reports suggest it is present in other cell
types, such as pancreatic acinar or smooth muscle cells
[25, 63]. Nevertheless, in all cell types, the principal GAG
chains are CS, except in mast cells where the covalently
attached GAG can be CS type E or heparin, depending on
their origin [25, 63]. In this study, we performed immuno-
histochemical analyses using the antibody CD117 to de-
tect mast cells in CRCs. The results showed a drastic
reduction in the population of mast cells in tumors com-
pared to non-tumor colon mucosa, a fact which may ex-
plain, at least in part, the observed decrease in protein
Fernández-Vega et al. BMC Cancer  (2015) 15:742 Page 15 of 20
expression. A small number of studies have described
alterations in the expression of serglycin in non
hematological tumors, such as increased expression in pa-
tients with hepatocellular and nasopharingeal carcinoma
[64, 65], where it has been related to unfavorable progno-
sis. Also, its elevated expression in aggressive breast can-
cer cells has also been reported [66].
The tissue-specific expression of individual HSPGs will
determine when and where HS chains are expressed
[13]. However, it should be taken into account that some
HSPGs can be hybrid molecules, carrying both HS and
CS side chains [67]. To generate the GAG chains the
regulated expression and action of multiple enzymes,
mainly GTs, (which are found in the lumen of the Golgi
apparatus) are required [13]. Both HS and CS chain bio-
synthesis begins with the formation of a tetrasaccharide
linkage region that comprises xylose-galactose-galactose-
GlcA. Our results revealed that transcript levels of the
different enzymes involved in the transfer and modifica-
tion of the xylose residue display different alterations in
CRCs. First, XYLT1 and XYLT2 appeared downregulated
in non-metastatic patients alone; these genes encode
two different xylosyltransferases (XylT1 and XylT2) that
transfer a xylose residue from UDP-xylose to the hy-
droxyl group of a serine on the core protein with differ-
ing efficiency and displaying different expression
patterns [68]. Modulation of the expression of xylosyl-
transferases has been described as regulator of GAG-
synthesis in rheumatoid conditions [69]. Second, the
transcription of FAM20B, which encodes xylose kinase
1 that catalyzes a transient phosphorilation of the Xyl
residue involved in the control of GAG biosynthesis
[70], also decreased significantly, though only in non-
metastatic tumors. In relation to the other enzymes in-
volved in the synthesis of the tetrasaccharide linker,
only B3GAT1, which encodes one of the three isoforms
of GlcA-transferase I responsible for the transfer of the
GlcA residue [28], appeared downregulated in both
types of tumors, although expression was more intense
in non-metastatic CRCs.
At this point, the process of GAG synthesis follows
one of two divergent paths, depending on whether the
addition of a GlcNAc or GalNAc residue takes place,
which leads to the synthesis of HS or CS/DS respect-
ively. EXTL2 and EXTL3 encode enzymes that possess
GlcA-transferase I activity, and thus direct the pathway
toward the synthesis of HS, although it has been de-
scribed that EXTL2 transfer of a GlcNAc residue to a
linkage region previously phosphorylated by xylose kin-
ase 1 terminates chain elongation, suggesting that
EXTL2 controls HS biosynthesis [70]. The ensuing
polymerization of the chain involves the consecutive
addition of alternating GlcA and GlcNAc residues, me-
diated by the action of two enzymes encoded by the
genes EXT1 and EXT2. At the level of transcription, the
only change found in this set of enzymes was a down-
regulation of EXT1 in non-metastatic CRCs. EXT1 and
EXT2 are tumor suppressors, associated with hereditary
multiple exostoses, characterized by the development of
benign skeletal tumors in patients [14]. Although in this
study EXTL3 did not show any significant alterations,
previous reports have described its down-regulation in
CRCs associated with mucinous differentiation and
caused by promoter methylation [21].
The addition of GalNA instead of GlcNAc to the linker
directs the pathway towards the biosynthesis of CS. In this
case, chain extension takes place through the sequential
addition of alternative GlcA and GalNAc residues. Five
genes, CSGALNACT1, CSGALNACT2, CHSY1, CHPF and
CHSY3 encode the GTs involved in this process [71]. The
expression of all except CHPF were found to decrease
in the group of non-metastatic tumors analyzed, while
in metastatic CRCs, CHPF alone appeared overex-
pressed. In previous studies of CRCs, a number of
changes have been described: a gradual increase in
chondroitin polymerizing factor with advancing cancer
stage; an increase in CHSY1 expression in normal tis-
sue adjacent to benign tumors compared to tumoral tis-
sues and high expression levels during the early stages;
and low expression levels of CHSY3 in both normal
and tumor specimens, although it must be stressed that
these studies involved colorectal cancers from different
locations and not only right sided CRCs [72].
Taken together, the alterations observed in our study
in the transcription of this category of genes suggests
variation in the GAG chains, particularly in non-
metastatic CRCs, while few changes were detected in
metastatic tumors. This fact is particularly noticeable in
the enzymes involved in the polymerization of CS, which
appear to be more affected than those involved in HS
polymerization. The decrease of the transcription of
some enzymes involved in the synthesis of the tetrasac-
charide linker, particularly FAM20B, could also be re-
lated. Variations in the level of GAGs for various tumor
types have been described elsewhere, both increases and
decreases. With respect to CRCs, a decrease in GAG
production has been described, as well as reductions in
levels of HS [19, 73]. Besides, some studies describe a re-
duction in CS levels in the neoplastic colon [73], while
other reports describe an increase, albeit predominantly
related to CS in the intercellular matrix produced by the
tissue surrounding the tumor [74].
The fine structure of HS ultimately depends on the
control of polymerization of the chains, but the expression
and action of multiple sulfotransferases and one epimerase
is also essential. As the polymer forms, the first reaction in-
volved in polymer modification involves removal of acetyl
groups from GlcNAc residues, followed by sulfation of the
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amino group which is catalyzed by four different isoforms
of N-deacetylase/N-sulfotransferases [13]. NDST1 and
NDST2 show broadly overlapping tissue distribution [28],
while NDST3 and NDST4 are more restricted and are
expressed principally during embryonic development [75].
Our analysis of colon CRCs was able to detect the exist-
ence of transcription of isoforms 1 and 2 in both tumoral
and normal samples, but not of isoforms 3 and 4. NDST1
and NDST2 appeared significantly underexpressed, but
only in non-metastatic tumors. These alterations are likely
to involve important consequences for the structure of HS
chains, since the reaction catalysed by this family of en-
zymes is essential for the creating of sulfated S-domains.
Lower N-sulfation levels in CRCs involving modifications
in both the S domains and their flanking mixed domains
have been reported [20, 76], although to our knowledge
there are no other studies that compare levels between tu-
mors with or without metastasis.
Further modifications of the HS chains include the
epimerization of GlcA into IdoA, catalyzed by the action
of the enzyme C5-GlcA epimerase and the addition of
O-sulfate groups at C2 of uronic acid and to C6 and C3
of the glucosamine residues [13, 14]. 2-O-sulfation is
closely associated with epimerization, and no alteration
in the transcription levels of the genes involved, GLCE
and HS2ST1, could be detected in CRCs in this study.
O-sulfation at C6 is carried out by enzymes encoded by
the genes HS6ST1, HS6ST2 and HS6ST3, each of which
differs in their substrate specificities and tissue expres-
sion [77]. HS6ST1 transcription here appeared decreased
in non-metastatic tumors only; the effect of this down-
regulation on the sulfation at C6 should be relevant,
since HS6ST1 is the principal isoform, HS3ST3 levels be-
ing found to be very low and to exhibit considerable
variation between patients, while HS6ST2 transcripts
were undetected. A reduction in 2-O-sulfation and an
increase in 6-O-sulfation in colon carcinoma cells has
been described, albeit related to HS from colon adenoma
cells [77], and other studies have, in addition, detected
the undersulfation of HS molecules in tumors [19].
The final family of enzymes involved in the biosyn-
thesis of HS are the 3-O-sulfotransferases, which in fact
form the largest group, comprising seven different mem-
bers, and which are implicated in the formation of spe-
cific HS motifs that interact in a selective manner with
specific protein ligands. Although 3-O-sulfation is a rela-
tively rare modification, and to date very few proteins
have been described that are influenced by it [78], sev-
eral studies have described their alteration in different
tumors. Such alterations may be upregulations, as in the
case of HS3ST1 and HS3ST3A1 in, respectively, hepato-
cellular cancer and glioblastoma [79, 80], or subexpres-
sions in, for example, HS3ST2 in breast, colon, lung and
pancreatic cancers [22], HS3ST1 and HS3ST3A1 in
chondrosarcoma cells and HS3ST4, HS3ST5 and
HS3ST6 in invasive breast ductal carcinomas [81, 82]. In
the present study, isoforms HS3ST3B1 and HS3ST5 ap-
peared underexpressed in non-metastatic CRCs. Not-
withstanding the implications of 3-O-sulfation decrease
in tumors being as yet known, it has been suggested that
certain patterns of 3-O-sulfation could impart cancerous
phenotypic changes [30].
Of the different sulfate groups present on the HS
chains, 6S modification is the only known sulfate moiety
known to be post-synthetically edited from the chain,
implying that it has special regulatory importance. Two
endosulfatases that are secreted from the Golgi and
localized on the cell surface, SULF1 and SULF2, se-
lectively remove 6-O-sulfate groups on GlcN residues
[27]. Alterations in the expression of these genes have
been reported in various tumors, involving either up or
downregulations depending on the neoplasia ivolved [17].
However, transcript levels of none of these genes were
found to be altered in any type of CRCs.
As indicated earlier, some HSPGs are hybrid mole-
cules, carrying both HS and CS side chains [67]. The al-
terations observed in this study in transcriptions of GTs
largely point towards changes in the CS chains. In
addition, changes in CSPGs associated with CRCs, for
example versican or decorin, have been described [83].
CS repeating disaccharide building units can be modified
by epimerization of GlcA residues and by sulfate groups
at C2 of uronic acids and at C4 and/or C6 of GalNAc
residues with various combinations [71]. In CRCs, the
expressions of the genes encoding the enzymes that
catalyze the different reactions which generate CS struc-
tures are altered, more than 60 % of them appearing
underexpressed. Interestingly, and in contrast to the
other groups of genes cited previously, the observed al-
terations were very similar in both tumor types, irre-
spective of presence or absence of lymph node
metastasis. Furthermore, the observed alterations in ex-
pression appear to affect all modifications, except sulfa-
tion at C6 of GalNAc, including epimerization and C2
sulfation of uronic acid. In the case of sulfation at C4 of
GalNAc, 3 of the 4 genes involved appeared downregu-
lated, the only one showing no significant difference,
CHST12, being the one which displayed the lowest levels
of transcription. In a previous study, the transcriptions
of two of these genes, CHST14 and CHST3, were ana-
lyzed and it was found that the expression of CHST3 did
not differ, while CHST14 decreased as the stage of the
cancer progressed [76] and, although the samples used
were from tumors from different locations, these data
support, at least in part, the results presented here. Di-
saccharide composition analysis carried out in other
studies have shown an increase in 6-sulfated and non-
sulfated disaccharides, while CS levels were not related
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with the metastatic potential of a tumor [76, 84]. Inter-
estingly, a recent study described a decrease in the levels
of CS in CRC, and this was accompanied by increases in
the levels of 6S and 4S6S (CS-E) disaccharide units com-
pared to normal tissue [73]. However, in our study we
were not able to detect any transcription of CHST15, the
gene which encodes the enzyme responsible for transfer-
ing sulfate to the C-6 of an already 4-O sulfated GalNAc
residue.
HPSE is an endo-β-D-glucuronidase that cleaves spe-
cific β-D-glucouronosyl-N-acetyl-glucosaminyl linkages,
yielding HS fragments of appreciable size which may
contain biologically active HS domains [29]. HPSE ex-
pression is induced in all the principal types of human
cancer and is often associated with reduced survival,
increased tumor metastasis and higher density of micro-
vessels [29]. Analysis of HPSE transcript levels in non-
metastatic CRCs in this study showed an apparent
decrease in 70 % of the patients analyzed, although the
dispersion of values in healthy tissues was considerably
higher than in tumoral tissues. In contrast, metastatic
tumors showed greater variability in their transcription
levels, varying from under to overexpression depending
on the individual patient concerned. Conversely, other
studies have found HPSE to be expressed at early stages
of neoplasia, although it was not detected in the adjacent
normal colon epithelium, and its expression gradually
increased as the cells progressed from well differentiated
to poorly differentiated colon carcinoma [85, 86]. In this
study, we were able to detect the expression of HPSE in
the adjacent normal-looking colon epithelium, a fact that
could be explained by the existence of inflammation
[87], or as due to the dynamic constant renewal of the
colon mucosa, this latter being a phenomena which has
been related to the unmethylated state of the HPSE pro-
moter in the normal colon [88].
HPSE2 is a homologue of heparanase that lacks HS-
degrading activity, although it is able to interact with HS
with a high affinity, and is capable of modulating HPSE
enzymatic activity and signaling properties, to the extent
that an anti-metastatic character has been proposed for
it [29, 89]. The downregulation of this protein has been
described in some neoplasms [82]. In CRCs, transcripts
for this gene were detected in 70 % of patients with non-
metastatic tumors, which was reduced to 30 % in those
cases showing lymph node metastasis, although the dis-
persion of the data meant that statistically significance
was not reached.
Conclusions
In summary, the analysis of differential expression of the
genes involved in the biosynthesis of HSPGs in right
sided CRCs indicates that a percentage of them showed
significant changes in their transcript levels. The number
of genes affected was higher in non-metastatic tumors,
involving around 40 % of all genes analyzed, while in
metastatic tumors the proportion of genes affected was
below 20 %. That said, all genes whose expression was
altered in metastatic CRCs also showed altered expres-
sion in non-metastatic tumors, the only exceptions being
syndecan-1 and CHPF. The variations observed seem to
have a strong effect on CS chains; in non-metastatic tu-
mors they affect most of the GTs responsible for the
polymerization of the saccharide chains as well as having
an effect on many enzymes involved in their modifica-
tion. In contrast, metastatic tumors maintain the alter-
ations in the modifying enzymes, but not those involving
the GTs. HS chains seem to experience far more limited
changes in metastatic CRCs than in non-metastatic tu-
mors. Moreover, PGs on the cell surface show significant
differences in expression depending on the presence or
absence of metastases, while alterations observed in pro-
teoglycans located in the extracellular matrix or within
the cell are very similar.
Additional file
Additional file 1: Table S1. qRT-PCR primer sequences. (DOC 253 kb)
Abbreviations
CRC: Colorectal cancer; CS: Chondroitin sulfate; DS: Dermatan sulfate;
ECM: Extracellular matrix; GAG: Glycosaminoglycan; GalNAc: N-acetyl-D-
galactosamine; GlcA: D-glucuronic acid; GlcNAc: N-acetyl-D-glucosamine;
GT: Glycosyltransferase; HS: Heparan sulfate; HSPG: Heparan sulfate
proteoglycan; IdoA: Iduronate.
Competing interests
The authors declare that thay have not competing interests.
Authors’ contributions
IFV carried out the qPCR experiments and contributed to compilation of
patient information and sample preparation. OG carried out the
histochemistry. BG contributed to qPCR experiments and histochemistry.
AC participated actively in providing advice and editing the manuscript.
AA supervised sample preparation, the compilation of patient information as
well as the immunohistochemical analyses. LMQ co-ordinated the study and
drafted the manuscript. All authors have read and approved the final
manuscript.
Acknowledgments
This work was supported in part by the Instituto de Salud Carlos III-Fondo de
Investigación Sanitaria (grant PI051564). The University Institute of Oncology
of Asturias is supported by Obra Social Cajastur, Asturias, Spain.
Author details
1Servicio de Patología. Hospital Universitario de Araba, Álava 01009, Spain.
2Department of Morphology and Cell Biology, University of Oviedo, 33006
Oviedo, Spain. 3University Institute of Oncology of Asturias, Oviedo, Spain.
4Department of Functional Biology, University of Oviedo, 33006 Oviedo,
Spain. 5Department of Biotechnology, Neiker-Tecnalia Arkaute, 01080
Vitoria-Gasteiz, Spain. 6Department of Pathology, Hospital, Universitario
Central de Asturias, 33006 Oviedo, Spain.
Received: 13 March 2015 Accepted: 8 October 2015
Fernández-Vega et al. BMC Cancer  (2015) 15:742 Page 18 of 20
References
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer
J Clin. 2005;55:74–108.
2. Manne U, Shanmugam C, Katkoori VR, Bumpers VR, Grizzle WE.
Development and progression of colorectal neoplasia. Cancer Biomark.
2010;9:235–65.
3. Richman S, Adlard J. Left and right sided large bowel cancer. BMJ.
2002;324:931–2.
4. Chau BN, Diaz RL, Saunders MA, Cheng C, Chang AN, Warrener P, et al.
Identification of SULF2 as a novel transcriptional target of p53 by use of
integrated genomic analyses. Cancer Res. 2009;69:1368–74.
5. Baraz L, Haupt Y, Elkin M, Peretz T, Vlodaysky I. Tumor suppressor p53
regulates heparanase gene expression. Oncogene. 2006;25:3939–47.
6. Truant S, Bruyneel E, Gouyer V, De Wever O, Pruvot FR, Mareet M, et al.
Requirement of both mucins and proteoglycans in cell-cell dissociation and
invasiveness of colon carcinoma HT-29 cells. Int J Cancer. 2003;104:683–94.
7. Rider CC. Heparin/heparan sulphate binding in the TGF-beta cytokine
superfamily. Biochem Soc Trans. 2006;34:458–60.
8. Lai JP, Oseini AM, Moser CD, Yu C, Elsawa SF, Hu C, et al. The oncogenic
effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part
by glypican 3-dependent Wnt activation. Hepatology. 2010;52:1680–9.
9. Sakane H, Yamamoto H, Matsumoto S, Sato A, Kikuchi A. Localization of
glypican-4 in different membrane microdomains is involved in the
regulation of Wnt signaling. J Cell Sci. 2012;125:449–60.
10. Zhao W, McCallum SA, Xiao Z, Zhang F, Linhardt RJ. Binding affinities of
vascular endothelial growth factor (VEGF) for heparin-derived
oligosaccharides. Biosci Rep. 2012;32:71–81.
11. Mahtouk K, Cremer FW, Rème T, Jourdan M, Baudard M, Moreaux J, et al.
Heparan sulphate proteoglycans are essential for the myeloma cell growth
activity of EGF-family ligands in multiple myeloma. Oncogene.
2006;25:7180–91.
12. Maglietta R, Liuzzi VC, Cattaneo E, Laczko E, Piepoli A, Panza A, et al.
Molecular pathways undergoing dramatic transcriptomic changes during
tumor development in the human colon. BMC Cancer. 2012;12:608.
13. Esko JD, Lindahl U. Molecular diversity of heparan sulphate. J Clin Invest.
2001;108:169–73.
14. Whitelock JM, Iozzo RV. Heparan sulfate: a complex polymer charged with
biological activity. Chem Rev. 2005;105:2745–64.
15. Park PW, Reizes O, Bernfields M. Cell surface heparan sulfate proteoglycans:
selective regulators of ligand-receptor encounters. J Biol Chem.
2000;275:29923–6.
16. Sanderson RD. Heparan sulfate proteoglycans in invasion and metastasis.
Semin Cell Dev Biol. 2001;12:89–98.
17. García-Suárez O, Fernández-Vega I, Quirós LM. Multiple alterations of
heparan sulfate in cancer. OA Cancer. 2013;1:1.
18. Park H, Kim Y, Lim Y, Han I, Oh ES. Syndecan-2 mediates adhesion and
proliferation of colon carcinoma cells. J Biol Chem. 2002;277:29730–6.
19. Bouziges F, Simon-Assmann P, Leberquier C, Marescaux J, Bellocq JP, Haffen
K, et al. Changes in glycosaminoglycan synthesis and in heparan sulfate
deposition in human colorectal adenocarcinomas. Int J Cancer.
1990;46:189–97.
20. Jayson GC, Lyon M, Paraskeva C, Turnbull JE, Deakin JA, Gallagher JT.
Heparan sulfate undergoes specific structural changes during the
progression from human colon adenoma to carcinoma in vitro. J Biol
Chem. 1998;273:51–7.
21. Karibe T, Fukui H, Sekikawa A, Shiratori K, Fujimori T. EXTL3 promoter
methylation down-regulates EXTL3 and heparan sulphate expression in
mucinous colorectal cancers. J Pathol. 2008;216:32–42.
22. Miyamoto K, Asada K, Fukutomi T, Okochi E, Yagi Y, Hasegawa T, et al.
Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-
sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic
cancers. Oncogene. 2003;22:274–80.
23. Schefe JH, Lehmann KE, Buschmann IR, Unger T, Funke-Kaiser H.
Quantitative real-time RT-PCR data analysis: current concepts and the novel
“gene expression’s CT difference” formula. J Mol Med. 2006;84:901–10.
24. Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold
Spring Harb Perspect Biol. 2011;3:1–34.
25. Kolset SO, Tveit H. Serglycin-structure and biology. Cell Mol Life Sci.
2008;65:1073–85.
26. Carlsson P, Kjellén L. Heparin biosynthesis. Handb Exp Pharmacol.
2012;207:23–41.
27. Kreuger J, Kjellén L. Heparan sulfate biosynthesis: regulation and variability.
J Histochem Cytochem. 2012;60:898–907.
28. Nairn AV, Kinoshita-Toyoda A, Toyoda H, Xie J, Harris K, Dalton S, et al.
Glycomics of Proteoglycan Biosynthesis in Murine Embryonic Stem Cell
Differentiation. J Proteome Res. 2007;6:4374–87.
29. Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I. The heparanase system
and tumor metastasis: is heparanase the seed and soil? Cancer Metast Rev.
2011;30:253–68.
30. Raman K, Kuberan B. Chemical Tumor Biology of Heparan Sulfate
Proteoglycans. Curr Chem Biol. 2010;4:20–31.
31. Theocharis A, Skandalis SS, Tzanakakis GN, Karamanos NK. Proteoglycans in
health and disease: novel roles for proteoglycans in malignancy and their
pharmacological targeting. FEBS J. 2010;277:3904–23.
32. Arvatz G, Barash U, Nativ O, Ilan N, Vlodaavsky I. Post-transcriptional
regulation of heparanase gene expression by a 3′ AU-rich element. FASEB J.
2010;24:4969–76.
33. Grobe K, Esko JD. Regulated translation of heparan sulfate N-acetylglucosamine
N-deacetylase/N-sulfotransferase isozymes by structured 5′-untranslated regions
and internal ribosome entry sites. J Biol Chem. 2002;277:30699–706.
34. Yeaman C, Rapraeger AC. Post-transcriptional regulation of syndecan-1
expression by cAMP in peritoneal macrophages. J Cell Biol. 1993;122:941–50.
35. Day RM, Hao X, Ilyas M, et al. Changes in the expression of syndecan-1 in
the colorectal adenoma-carcinoma sequence. Virchows Arch. 1999;434:121–5.
36. Peretti T, Waisberg J, Mader AM, de Matos LL, da Costa RB, Conceicao GM,
et al. Heparanase-2, syndecan-1, and extracellular matrix remodeling in
colorectal carcinoma. Eur J Gastroenterol Hepatol. 2008;20:756–65.
37. Hashimoto Y, Skacel M, Adams JC. Association of loss of epithelial
syndecan-1 with stage and local metastasis of colorectal adenocarcinomas:
an immunohistochemical study of clinically annotated tumors. BMC Cancer.
2008;8:185.
38. Mitselou A, Skoufi U, Tsimogiannis KE, Briasoulis E, Vougiouklakis T, Arvanitis
D, et al. Association of syndecan-1 with angiogenesis-related markers,
extracellular matrix components, and clinicopathological features in
colorectal carcinoma. Anticancer Res. 2012;32:3977–85.
39. Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, et al.
Syndecan-1 expression is up-regulated in pancreatic but not in other
gastrointestinal cancers. Int J Cancer. 2000;88:12–20.
40. Szatmári T, Dobra K. The Role of Syndecan-1 in Cellular Signaling and its
Effects on Heparan Sulfate Biosynthesis in Mesenchymal Tumors. Front
Oncol. 2013;3:310.
41. Filmus J, Capurro M, Rast J. Glypicans. Genome Bio. 2008;9:224.
42. Suhovskih AV, Mostovich LA, Kunin IS, Boboev MM, Neopmnyashchikh GI,
Aidagulova SV, et al. Proteoglycan expression in normal human prostate
tissue and prostate cancer. ISRN Oncol. 2013;2013:680136.
43. Su G, Meyer K, Nandini CD, Qiao D, Salamat S, Friedl A. Glypican-1 is
frequently overexpressed in human gliomas and enhances FGF-2 signaling
in glioma cells. Am J Pathol. 2006;168:2014–206.
44. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Büchler MW, Korc M. The cell-
surface heparan sulfate proteoglycan glypican-1 regulates growth factor
action in pancreatic carcinoma cells and is overexpressed in human
pancreatic cancer. J Clin Invest. 1998;102:1662–7.
45. Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, et al.
Glypican-1 is overexpressed in human breast cancer and modulates the
mitogenic effects of multiple heparin-binding growth factors in breast
cancer cells. Cancer Res. 2001;61:5562–9.
46. García-Suárez O, García B, Fernández-Vega I, Astudillo A, Quirós LM.
Neuroendocrine tumors show altered expresión of chondroitin sulfate,
glypican 1, glypican 5, and syndecan 2 depending on their differentiation
grade. Front Oncol. 2014;4:15.
47. Fico A, Maina F, Dono R. Fine-tuning of cell signalling by glypicans. Cell Mol
Life Sci. 2011;68:923–9.
48. Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, et al. Gene expression
profiling reveals potential biomarkers of human hepatocellular carcinoma.
Clin Cancer Res. 2007;13:1133–9.
49. Lau CS, Yu CB, Wong HK, Fan DS, Wong KW, Lam DS, et al. Allelic imbalance
at 13q31 is associated with reduced GPC6 in Chinese with sporadic
retinoblastoma. Br J Ophthalmol. 2010;94:357–62.
50. Campos-Xavier AB, Martinet D, Bateman J, Belluoccio D, Rowley L, Tan TY,
et al. Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6)
impair endochondral ossification and cause recessive omodysplasia. Am J
Hum Genet. 2009;84:760–70.
Fernández-Vega et al. BMC Cancer  (2015) 15:742 Page 19 of 20
51. Yiu GK, Kaunisto A, Chin YR, Toker A. NFAT promotes carcinoma invasive
migration through glypican-6. Biochem J. 2011;440:157–66.
52. Cooper DL, Dougherty GJ. To metastasize or not? Selection of CD44 splice
sites. Nat Med. 1995;1:635–7.
53. Kuniyasu H, Oue N, Tsutsumi M, Tahara E, Yasui W. Heparan sulfate
enhances invasion by human colon carcinoma cell lines through expression
of CD44 variant exon 3. Clin Cancer Res. 2001;7:4067–72.
54. Hempel N, How T, Dong M, Murphy S, Fileds TA, Blobe GC. Loss of
betaglycan expression in ovarian cancer: role in motility and invasión.
Cancer Res. 2007;67:5231–8.
55. Bernabeu C, Lopez-Novoa JM, Quintanilla M. The emerging role of
TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta.
2009;1792:954–73.
56. Criswell TL, Dumont N, Barnett JV, Arteaga CL. Knockdown of the
transforming growth factor-beta type III receptor impairs motility and
invasion of metastatic cancer cells. Cancer Res. 2008;68:7304–12.
57. Woszczyk D, Gola J, Jurzak M, Mazurek U, Mykata-Ciesla J, Wilczok T.
Expression of TGF beta1 genes and their receptor types I, II, and III in
low- and high-grade malignancy non-Hodgkin’s lymphomas. Med Sci
Monit. 2004;10:33–7.
58. Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J, et al.
Identification of a global gene expression signature of B-chronic
lymphocytic leucemia. Mol Cancer Res. 2003;1:346–61.
59. Iozzo RV, Zoeller JJ, Nyström A. Basement membrane proteoglycans:
modulators Par Excellence of cancer growth and angiogenesis. Mol Cells.
2009;27:503–13.
60. Xinnong J, Couchman J. Perlecan and tumor angiogenesis. J Histochem
Cytochem. 2003;51:1393–410.
61. Nielsen JS, McNagny KM. Novel functions of the CD34 family. J Cell Sci.
2008;121:3683–92.
62. Li Q, Olsen BR. Increased angiogenic response in aortic explants of collagen
XVIII/endostatin-null mice. Am J Pathol. 2004;165:415–24.
63. Korpetinou A, Skandalis SS, Labropoulou VT, Smirlaki G, Noulas A,
Karamanos NK, et al. Serglycin: At the Crossroad of Inflammation and
Malignancy. Front Oncol. 2014;3:327.
64. He L, Zhou X, Qu C, Tang Y, Zhang Q, Hong J. Serglycin (SRGN)
overexpression predicts poor prognosis in hepatocellular carcinoma
patients. Med Oncol. 2013;30:707.
65. Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, et al. Serglycin is a
theranostic target in nasopharyngeal carcinoma that promotes metastasis.
Cancer Res. 2011;71:3162–72.
66. Korpetinou A, Skandalis SS, Moustakas A, Happonen KE, Tveit H, Prydz K, et
al. Serglycin is implicated in the promotion of aggressive phenotype of
breast cancer cells. PLoS One. 2013;8:10.
67. Iozzo RV. Heparan sulfate proteoglycans: intrincate molecules with
intriguing functions. J Clin Invest. 2001;108:165–7.
68. Pönighaus C, Ambrosius M, Casanova JC, Prante C, Kuhn J, Esko JD, et al.
Human xylosyltransferase II is involved in the biosynthesis of the uniform
tetrasaccharide linkage region in chondroitin sulphate and heparan
sulphate proteoglycans. J Biol Chem. 2007;282:5201–6.
69. Venkatesan N, Barré L, Magdalou J, Mainard D, Netter P, Fournel-Gigleux S,
et al. Modulation of xylosyltransferase I expression provides a mechanism
regulating glycosaminoglycan chain synthesis during cartilage destruction
and repair. FASEB J. 2009;23:813–22.
70. Nadanaka S, Zhou S, Kagiyama S, Shoji N, Sugahara K, Sugihara K, et al.
EXTL2, a member of EXT family of tumor suppressor, controls
glycosaminoglycan biosynthesis in a xylose kinase-dependent manner.
J Biol Chem. 2013;288:9321–33.
71. Mizumoto S, Ikegawa S, Sugahara K. Human genetic disorders caused by
mutations in genes encoding biosynthetic enzymes for sulfated
glycosaminoglycans. J Biol Chem. 2013;288:10953–61.
72. Kalathas D, Theocharis DA, Bounias D. Chondroitin synthases I, II, III and
chondroitin sulfate glucuronyltransferase expression in colorectal cancer.
Mol Med Rep. 2011;4:363–8.
73. Joo EJ, Weyers A, Li G, Gasimli L, Li L, Choi WJ, et al. Carbohydrate-
Containing Molecules as Potential Biomarkers in Colon Cancer. OMICS.
2014;18:231–41.
74. Iozzo RV, Bolender RP, Wight TN. Proteoglycan changes in the intercellular
matrix of human colon carcinoma: an integrated biochemical and
stereologic analysis. Lab Invest. 1982;47:124–38.
75. Grobe K, Ledin J, Ringvall M, Holmborn K, Forsberg E, Esko JD, et al.
Heparan sulfate and development: differential roles of the N-
acetylglucosamine N-deacetylase/N-sulfotransferase isozymes. Biochim
Biophys Acta. 2002;1573:209–15.
76. Kalathas D, Theocharis DA, Bounias D, Kyriakopoulou D,
Papageorgakopoulou N, Stavropoulos MS, et al. Alterations of
glycosaminoglycan disaccharide content and composition in colorectal
cancer: structural and expressional Studies. Oncol Rep. 2009;22:369–75.
77. Smeds E, Habuchi H, Do AT, Hjertson E, Grundberg H, Kimata K, et al.
Substrate specificities of mouse heparan sulphate glucosaminyl 6-O-
sulphotransferases. Biochem J. 2003;372:371–80.
78. Thacker BE, Xu D, Lawrence R, Esko JD. Heparan sulfate 3-O-sulfation: A rare
modification in search of a function. Matrix Biol. 2014;30:60–72.
79. Tátrai P, Egedi K, Somorácz A, van Kuppevelt TH, Ten Dam G, Lyon M, et al.
Quantitative and qualitative alterations of heparan sulphate in fibrogenic
liver diseases and hepatocellular cancers. J Histochem Cytochem.
2010;58:429–41.
80. Wade A, Robinson AE, Engler JR, Petrisch C, James CD, Phillips JJ.
Proteoglycans and their roles in brain cancer. FEBS J. 2013;280:2399–417.
81. Bui C, Ouzzine M, Talhaoui I, Sharp S, Prydz K, Coughtrie MW, et al.
Epigenetics: methylation-associated repression of heparan sulfate 3-O-
sulfotransferase gene expression contributes to the invasive phenotype of
H-EMC-SS chondrosarcoma cells. FASEB J. 2010;24:436–50.
82. Fernández-Vega I, García O, Crespo A, Castañón S, Menéndez P, Astudillo A,
et al. Specific genes involved in synthesis and editing of heparan sulphate
proteoglycans show altered expression patterns in breast cancer. BMC
Cancer. 2013;13:24.
83. Asimakopoulou AP, Theocharis AD, Tzanakakis GN, Karamanos NK. The
biological role of chondroitin sulfate in cancer and chondroitin-based
anticancer agents. In Vivo. 2008;22:385–9.
84. Theocharis AD, Theocharis DA. High-performance capillary electrophoretic
analysis of hyaluronan and galactosaminoglycan-disaccharides in
gastrointestinal carcinomas. Differential disaccharide composition as a
possible tool-indicator for malignancies. Biomed Chromatogr. 2002;16:157–61.
85. Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I, et al.
Expression of heparanase in normal, dysplastic, and neoplastic human
colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis.
Am J Pathol. 2000;157:1167–75.
86. Nobuhisa T, Naomoto Y, Ohkawa T, Takaoka M, Ono R, Murata T, et al.
Heparanase expression correlates with malignant potential in human colon
cancer. J Cancer Res Clin Oncol. 2005;131:229–37.
87. Hermano E, Lerner I, Elkin M. Heparanase enzyme in chronic inflammatory
bowel disease and colon cancer. Cell Mol Life Sci. 2012;69:2501–13.
88. Peerless Y, Simon E, Sabo E, Ben-Izhak O, Hershkovitz D. Normal colon tissue
and colon carcinoma show no difference in heparanase promoter
methylation. Exp Mol Pathol. 2013;94:309–13.
89. Levy-Adam F, Feld S, Cohen-Kaplan V, Shteingauz A, Gross M, Arvatz G, et al.
Heparanase 2 interacts with heparan sulfate with high affinity and inhibits
heparanase activity. J Biol Chem. 2010;285:28010–9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Fernández-Vega et al. BMC Cancer  (2015) 15:742 Page 20 of 20
